{"entity":"abbott-laboratories","id":"ent_abbott-laboratories","name":"Abbott Laboratories","wikidata":"Q306764","page":"https://asof.is/record/abbott-laboratories","summary":"Abbott Laboratories is an American global health care and medical device products company, headquartered in Abbott Park. It reported revenue of $41.95B for the period ended December 31, 2024.","title":"Abbott Laboratories: revenue $41.95B","key_facts":[{"label":"CFO","value":"Philip P. Boudreau","claim":"clm_216BEF8E327D"},{"label":"Headquarters","value":"Abbott Park","claim":"clm_47ECD384B983"},{"label":"Revenue","value":"$41.95B","recorded":"41,950,000,000 United States dollar","note":"to 2024-12-31","claim":"clm_AC0EC8434FB1"},{"label":"Ticker","value":"ABT · NYSE","claim":"clm_E39037FF4684"}],"faq":[{"question":"Where is Abbott Laboratories headquartered?","answer":"Abbott Park."},{"question":"What is Abbott Laboratories's revenue?","answer":"$41.95B for the period ended December 31, 2024."}],"as_of":"2025-11-09","known_by":null,"since":null,"fact_pages":[{"predicate":"cfo","page":"https://asof.is/record/abbott-laboratories/cfo","md":"https://asof.is/record/abbott-laboratories/cfo.md","json":"https://asof.is/v1/entities/abbott-laboratories/cfo"},{"predicate":"headquarters","page":"https://asof.is/record/abbott-laboratories/headquarters","md":"https://asof.is/record/abbott-laboratories/headquarters.md","json":"https://asof.is/v1/entities/abbott-laboratories/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/abbott-laboratories/revenue","md":"https://asof.is/record/abbott-laboratories/revenue.md","json":"https://asof.is/v1/entities/abbott-laboratories/revenue"},{"predicate":"net_income","page":"https://asof.is/record/abbott-laboratories/net_income","md":"https://asof.is/record/abbott-laboratories/net_income.md","json":"https://asof.is/v1/entities/abbott-laboratories/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/abbott-laboratories/operating_income","md":"https://asof.is/record/abbott-laboratories/operating_income.md","json":"https://asof.is/v1/entities/abbott-laboratories/operating_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/abbott-laboratories/quarterly_revenue","md":"https://asof.is/record/abbott-laboratories/quarterly_revenue.md","json":"https://asof.is/v1/entities/abbott-laboratories/quarterly_revenue"}],"products":[],"coverage":{"entity":"abbott-laboratories","name":"Abbott Laboratories","kind":"organization","sources":[{"source":"wikidata","item":"Q306764","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":1800,"ticker":"ABT","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":548,"open":25,"retracted":0,"first":"1888-01-01","predicates":{"shares_outstanding":{"claims":70,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":76,"open":1,"kind":"fact"},"total_assets":{"claims":72,"open":1,"kind":"fact"},"quarterly_net_income":{"claims":42,"open":1,"kind":"fact"},"quarterly_operating_income":{"claims":56,"open":1,"kind":"fact"},"research_and_development":{"claims":9,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":56,"open":1,"kind":"fact"},"total_equity":{"claims":73,"open":1,"kind":"fact"},"revenue":{"claims":19,"open":1,"kind":"fact"},"net_income":{"claims":15,"open":1,"kind":"fact"},"quarterly_research_and_development":{"claims":28,"open":1,"kind":"fact"},"operating_income":{"claims":19,"open":1,"kind":"fact"},"cfo":{"claims":1,"open":1,"kind":"fact"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"headquarters":{"claims":2,"open":2,"kind":"fact"},"x_username":{"claims":1,"open":1,"kind":"identifier"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"agreement":{"claims":1,"open":1,"kind":"event"},"registrant_name":{"claims":1,"open":1,"kind":"fact"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"cik":{"claims":1,"open":1,"kind":"identifier"},"ticker":{"claims":1,"open":1,"kind":"identifier"},"website":{"claims":1,"open":1,"kind":"identifier"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":545,"last_added":"2026-11-08","last_checked":"2026-11-09","last_verified":null},{"origin":"wikidata","label":"Wikidata statements that cite a reference URL (wikidata_ingest.py)","claims":3,"last_added":"2026-11-08","last_checked":"2026-11-09","last_verified":null}],"gaps":["ceo: none public; unknown, not absent: a claim is published only once checked against its source","posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_4D88D9F7190C","predicate":"cash_and_equivalents","value":"7,511,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 7,511,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_4D88D9F7190C, https://asof.is/claim/clm_4D88D9F7190C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_4D88D9F7190C","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C0C2E64C6F88","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-10-29"}},{"id":"clm_216BEF8E327D","predicate":"cfo","value":"Philip P. Boudreau","valid_from":"2023-01-01","valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cfo: Philip P. Boudreau\", as of 2023-01-01. Claim clm_216BEF8E327D, https://asof.is/claim/clm_216BEF8E327D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm.","url":"https://asof.is/claim/clm_216BEF8E327D","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm","tier":"primary","publisher":"SEC EDGAR 10-K","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"Philip P. Boudreau, 53 2024 to present — Executive Vice President, Finance a nd Chief Financial Officer. 2023 to 2024 — Senior Vice President, Finance a nd Chief Financial Officer.","url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm"}},{"id":"clm_DC766CB8ACA6","predicate":"cik","value":"0000001800","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cik: 0000001800\", undated. Claim clm_DC766CB8ACA6, https://asof.is/claim/clm_DC766CB8ACA6, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_DC766CB8ACA6","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_7EA8A2BEA2BF","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories fiscal year end: 12-31\", undated. Claim clm_7EA8A2BEA2BF, https://asof.is/claim/clm_7EA8A2BEA2BF, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_7EA8A2BEA2BF","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_47ECD384B983","predicate":"headquarters","value":"Abbott Park","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories headquarters: Abbott Park\", undated. Claim clm_47ECD384B983, https://asof.is/claim/clm_47ECD384B983, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_47ECD384B983","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_F43E6397059E","predicate":"headquarters","value":"North Chicago","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories headquarters: North Chicago\", undated. Claim clm_F43E6397059E, https://asof.is/claim/clm_F43E6397059E, accessed 2026-11-10. Source: https://www.med-dept.com/resources/ww2-medical-equipment-manufacturers-and-suppliers/.","url":"https://asof.is/claim/clm_F43E6397059E","accessed":"2026-11-10"},"confidence":0.45,"status":"unverified","assertable":false,"why_not":"low_confidence","superseded_by":null,"sources":[{"url":"https://www.med-dept.com/resources/ww2-medical-equipment-manufacturers-and-suppliers/","tier":"secondary","publisher":null,"published_at":null},{"url":"https://www.wikidata.org/wiki/Q306764","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"Abbott Laboratories, Inc. – North Chicago, Illinois","url":"https://www.med-dept.com/resources/ww2-medical-equipment-manufacturers-and-suppliers/"}},{"id":"clm_349DE9490A94","predicate":"listed_on","value":"NYSE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories listed on: NYSE\", undated. Claim clm_349DE9490A94, https://asof.is/claim/clm_349DE9490A94, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_349DE9490A94","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_CF3E98D0B268","predicate":"net_income","value":"13,402,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 13,402,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_CF3E98D0B268, https://asof.is/claim/clm_CF3E98D0B268, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm.","url":"https://asof.is/claim/clm_CF3E98D0B268","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_76AC317902A6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-21T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-21"}},{"id":"clm_6578DDE458E0","predicate":"operating_income","value":"6,825,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 6,825,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_6578DDE458E0, https://asof.is/claim/clm_6578DDE458E0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm.","url":"https://asof.is/claim/clm_6578DDE458E0","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_551396362E4C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-21T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-21"}},{"id":"clm_2BCC0DA601EA","predicate":"quarterly_net_income","value":"1,644,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,644,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_2BCC0DA601EA, https://asof.is/claim/clm_2BCC0DA601EA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_2BCC0DA601EA","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0713CDEDD078","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-29"}},{"id":"clm_94C2592AE159","predicate":"quarterly_operating_income","value":"2,057,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 2,057,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_94C2592AE159, https://asof.is/claim/clm_94C2592AE159, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_94C2592AE159","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1C0A2724D779","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-29"}},{"id":"clm_1266BBB313EF","predicate":"quarterly_research_and_development","value":"766,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 766,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_1266BBB313EF, https://asof.is/claim/clm_1266BBB313EF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_1266BBB313EF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F408F42211E9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2025, filed 2025-10-29"}},{"id":"clm_4D4D4E6FC869","predicate":"quarterly_revenue","value":"11,369,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 11,369,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_4D4D4E6FC869, https://asof.is/claim/clm_4D4D4E6FC869, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_4D4D4E6FC869","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EF0BC6C103EE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2025, filed 2025-10-29"}},{"id":"clm_78E1BC94DC92","predicate":"registrant_name","value":"ABBOTT LABORATORIES","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories registrant name: ABBOTT LABORATORIES\", undated. Claim clm_78E1BC94DC92, https://asof.is/claim/clm_78E1BC94DC92, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_78E1BC94DC92","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_AD76C5C835C9","predicate":"research_and_development","value":"2,844,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories research and development: 2,844,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_AD76C5C835C9, https://asof.is/claim/clm_AD76C5C835C9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm.","url":"https://asof.is/claim/clm_AD76C5C835C9","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0537D98543E9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-21T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2024, filed 2025-02-21"}},{"id":"clm_AC0EC8434FB1","predicate":"revenue","value":"41,950,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 41,950,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_AC0EC8434FB1, https://asof.is/claim/clm_AC0EC8434FB1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm.","url":"https://asof.is/claim/clm_AC0EC8434FB1","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7C1D7352CFA6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-21T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2024, filed 2025-02-21"}},{"id":"clm_0F8EC0C78816","predicate":"shares_outstanding","value":"1,738,871,947 shares","valid_from":"2025-09-30","valid_to":"2026-01-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,738,871,947 shares\", as of 2025-09-30 (until 2026-01-31). Claim clm_0F8EC0C78816, https://asof.is/claim/clm_0F8EC0C78816, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_0F8EC0C78816","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_98DC25486509","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-10-29"}},{"id":"clm_AB7AA73DD6DF","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_AB7AA73DD6DF, https://asof.is/claim/clm_AB7AA73DD6DF, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_AB7AA73DD6DF","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_5EB4D6DCC26A","predicate":"state_of_incorporation","value":"IL","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories state of incorporation: IL\", undated. Claim clm_5EB4D6DCC26A, https://asof.is/claim/clm_5EB4D6DCC26A, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_5EB4D6DCC26A","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_E39037FF4684","predicate":"ticker","value":"ABT","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories ticker: ABT\", undated. Claim clm_E39037FF4684, https://asof.is/claim/clm_E39037FF4684, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_E39037FF4684","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_87D9C9A99CA7","predicate":"total_assets","value":"84,181,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 84,181,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_87D9C9A99CA7, https://asof.is/claim/clm_87D9C9A99CA7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_87D9C9A99CA7","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_61EE170DDFF9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-10-29"}},{"id":"clm_D5EE83B1870A","predicate":"total_equity","value":"50,954,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 50,954,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_D5EE83B1870A, https://asof.is/claim/clm_D5EE83B1870A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_D5EE83B1870A","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_233C6F73AC72","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-10-29"}},{"id":"clm_E677AE124C79","predicate":"website","value":"https://abbott.com","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories website: https://abbott.com\", undated. Claim clm_E677AE124C79, https://asof.is/claim/clm_E677AE124C79, accessed 2026-11-10. Source: https://www.wikidata.org/wiki/Q306764.","url":"https://asof.is/claim/clm_E677AE124C79","accessed":"2026-11-10"},"confidence":0.45,"status":"unverified","assertable":false,"why_not":"low_confidence","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q306764","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"Abbott Laboratories.","url":"https://www.abbott.com/en-us/homepage"}},{"id":"clm_4CCD509B66A0","predicate":"x_username","value":"AbbottNews","valid_from":"2011-08-22","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories x username: AbbottNews\", as of 2011-08-22. Claim clm_4CCD509B66A0, https://asof.is/claim/clm_4CCD509B66A0, accessed 2026-11-10. Source: https://www.wikidata.org/wiki/Q306764.","url":"https://asof.is/claim/clm_4CCD509B66A0","accessed":"2026-11-10"},"confidence":0.6,"status":"unverified","assertable":false,"why_not":"unverified","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q306764","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"https://twitter.com/AbbottNews","url":"https://abbott.com"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{"low_confidence":"Confidence below 0.5, the line the record asserts at.","unverified":"Unverified: one source that is not primary, or a primary source below confidence 0.7. Asserted once a primary source or a second independent domain confirms it."},"checked_by":{"sec-filing":"parsed from the SEC filing","page-read":"its source page states the value and the date","own-site":"the entity's own site names it (a website whose page names the entity, a handle its website links to)"}}}